Company Overview of Visionary Pharmaceuticals, Inc.
Visionary Pharmaceuticals, Inc., a biotechnology company, develops small molecule therapies for unmet medical needs in cancer and inflammation. It also specializes in translating chemical entities to the clinic and delivers nuclear receptor modulators to treat rheumatoid arthritis, multiple sclerosis, psoriasis, COPD, and cancer. The company’s product portfolio includes immunomodulators of Th17 T-helper lymphocytes for inflammation and Warburg effect inhibitors for cancer. It focuses on developing potent and selective antagonists of the retinoic acid receptor-related orphan nuclear receptor ROR?, a specific isoform expressed in lymphocytes; and novel inhibitors that modulate the aberrant met...
11555 Sorrento Valley Road
San Diego, CA 92121-1331
Founded in 2010
Key Executives for Visionary Pharmaceuticals, Inc.
Co-Founder, Chief Executive Officer, President and Director
Co-Founder, Vice President of Biology and Director
Compensation as of Fiscal Year 2014.
Visionary Pharmaceuticals, Inc. Key Developments
Visionary Pharmaceuticals, Inc. and BioBlocks, Inc. Announce Drug Discovery Collaboration Targeting Serum and Glucocorticoid-Regulated Kinase 1
Jan 8 14
Visionary Pharmaceuticals, Inc. and BioBlocks, Inc. announced the companies have established a collaboration for the discovery and development of novel small molecule inhibitors of Serum and Glucocorticoid-Regulated Kinase 1 (SGK1). This kinase has been implicated in tumorigenesis of various solid tumors including non-small cell lung cancer, breast, prostate and colorectal cancer. Importantly, SGK1 is a critical mediator of chemoresistance in triple negative breast cancer and other cancers. Together these cancers represent a significant unmet medical need. The parties will combine their respective technologies and expertise to generate superior leads in novel patentable space. BioBlocks' contribution includes its Leap-to-Lead(TM) small molecule lead discovery platform comprised of its proprietary physical fragment libraries and the Syntheverse(TM) virtual library, a vast database of feasible molecules providing solutions for fragment evolution. Visionary's contributions include its BindingSIGHTS(TM) technology platform comprised of a suite of computational algorithms and knowledge engine which identifies critical inhibitory hotspots in kinase enzyme active sites.
Visionary Pharmaceuticals, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 04:30 PM
Oct 2 13
Visionary Pharmaceuticals, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 04:30 PM. Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries